RENBP and COVID-19: In scenarios where both Ag and PCR COVID-19 surveillance testing strategies were available (Table 2), Ag testing was cost-effective compared with no surveillance from both the healthcare payer perspective (ICER=$112,351 per QALY gained) and the societal perspective (ICER=$9,627 per QALY gained) at 75% vaccination coverage.